Immunicum AB
Immunicum’s abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago

Immunicum AB 

27.03.2014 10:25

Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Göteborg, Sweden, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) -- Immunicum today
announced that an abstract has been approved to for presentation at the
American Society of Clinical Oncology's's, ASCO, annual convention held in
Chicago May 30-June 3, 2014. 

The abstract, with title 'Intratumoral vaccination with activated allogeneic
dendritic cells in patients with newly diagnosed metastatic renal cell
carcinoma (mRCC)', presents clinical data from the newly finalized phase
I/II-study on kidney cancer patients treated with INTUVAX(R). 

-       Being accepted to present at the most prestigious cancer conference in
the world creates a great opportunity for us to showcase Immunicum's technology
and shows the level of scientific interest our clinical data has generated,
says Immunicum's CEO, Jamal El-Mosleh. 

Immunicum recently received the results of the data for the phase I/II In trial
in patients with metastatic renal cell carcinoma (mRCC)' 

'We are pleased to report conclusions that can be crucial for the survival time
in patients with mRCC' says Jamal El-Mosleh, the CEO of Immunicum. 

During the ASCO annual meeting more data is to be presented to the meeting
participants and the media. 

Immunicum's immunotherapy plattforms are based on over 30 years of research in
the field of transplantation immunology. The Company's shares have been traded
since April 22, 2013 on NASDAQ OMX First North under the ticker IMMU. 



For further information please contact:

Jamal El-Mosleh, CEO of Immunicum, +4631-41 50 53,
jamal.el-mosleh@immunicum.com

Redeye AB is chosen as the Company's Certified Adviser.

Tel: +468-545 013 31. www.redeye.se.



About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of
therapeutic cancer vaccines, SUBCUVAX(R) and INTUVAX(R), and the method of
expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded
discovery of the dendritic cell and its central role in the activation of the
specific immune response. Since the raw material consists of allogeneic
dendritic cells, Immunicum's products can be produced in large scale. The
vaccines are now undergoing clinical trials in renal cell carcinoma and
hepatocellular carcinoma. 

www.immunicum.com
News Source: NASDAQ OMX



27.03.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Immunicum AB
              
               
              Sweden
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         SE0005003654
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------